<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174549</url>
  </required_header>
  <id_info>
    <org_study_id>LT001</org_study_id>
    <nct_id>NCT02174549</nct_id>
  </id_info>
  <brief_title>Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer</brief_title>
  <official_title>Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teclison Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teclison Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating
      agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer
      patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4
      nodules are eligible. Tirapazamine will be given by intra-arterial injection before
      embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat
      treatment is necessary only if disease progression. Expansion cohorts are open for metastatic
      gastrointestinal cancer and neuroendocrine tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 3+3 design for dose escalation. Each cohort will have 3-6 patients based on
      tolerability. Patients will receive escalated doses of tirapazamine until maximally tolerated
      dose. Embolization is performed per standard practice using Lipiodol and Gelfoam under X-ray
      guidance. Once a suitable dose is determined, an expansion cohort of 15 patients will be
      treated with the recommended phase 2 dose to determine preliminary efficacy. Expansion
      cohorts include (1) hepatocellular carcinoma, (2) metastatic solid tumors with liver
      metastasis, and (3) neuroendocrine tumor. Adverse events are evaluated by CTCAE vs. 4.0 and
      efficacy is evaluated by MRI using modified RECIST criteria and RECIST criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, dose escalation 3+3 design; 3 expansion cohorts: hepatocellular carcinoma, advanced solid tumors and neuroendocrine tumor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the recommended phase 2 dose</measure>
    <time_frame>2 years</time_frame>
    <description>future dose used for randomzied trials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>2 years</time_frame>
    <description>mRECIST based on mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>From randomization to progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>PK parameter</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Gastrointestinal Cancer Metastatic</condition>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Tirapazamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirapazamine</intervention_name>
    <description>Intra-arterial injection into the tumor feeding artery</description>
    <arm_group_label>Tirapazamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial embolization (TAE)</intervention_name>
    <description>Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia</description>
    <arm_group_label>Tirapazamine</arm_group_label>
    <other_name>Lipiodol and Gelfoam as the standard embolizing agents.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Confirmed diagnosis of HCC &gt; 10 mm with a characteristic 4-phase CT or dynamic
             contrast enhanced MRI finding showing intense arterial uptake followed by &quot;washout&quot; of
             contrast in the venous-delayed phases per American Association for the Study of Liver
             Disease (AASLD) criteria.

          -  Patients between ages 20 and 80

          -  Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for
             surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the
             largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients
             with liver metastatic gastrointestinal cancer, including neuroendocrine tumor

          -  Patients are candidates for TAE or Transarterial ChemoEmbolization (TACE). No tumor
             invasion to portal vein or thrombosis in portal vein.

          -  ECOG score 0-1 with no known cardiac, pulmonary or renal dysfunction

          -  Child-Pugh score group A or B7 liver functional score

          -  Prior local therapies such as surgical resection, radiofrequency ablation, or alcohol
             injection are allowed as long as tumor progresses from the prior treatment and the
             patients are still candidates for TAE. All prior therapy must be at least 4 weeks
             prior to enrollment and free from treatment-related toxicity.

          -  No TAE/TACE in the past

          -  Patients have normal organ function: ANC ≥ 1000 /µL, Hemoglobin ≥ 9 gm/dL, Platelets ≥
             50,000 /µL, Creatinine ≤ 2 mg/dL, AST and ALT &lt; 5 X upper normal limit of the current
             institution; bilirubin ≤ 3.0 mg/dL, PT prolongation no more than 4 sec above upper
             limit of normal.

        For the expansion cohort of neuroendocrine tumor or metastatic gastrointestinal cancer

          -  Unresectable, locally advanced or metastatic, well differentiated (low or intermediate
             grade), neuroendocrine tumors (NET).

          -  Liver metastatic gastrointestinal cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Abi-Jaoudeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linta Garcia, PhD</last_name>
    <email>linta_garcia@teclison.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ray Lee, MD PhD</last_name>
    <email>ray.lee01@teclison.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Berg</last_name>
      <phone>714-456-7687</phone>
      <email>jdberg@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curt Johnson</last_name>
      <phone>415-353-2310</phone>
      <email>curt.johanson@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>Embolization</keyword>
  <keyword>Tirapazamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirapazamine</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

